Oncoguard Liver

A new approach for early-stage HCC detection

Liver cancer is the fastest-growing cause of cancer-related death in the United States.1 By 2035, it is expected to be a third leading cause of cancer-related death, surpassing breast and prostate cancer.2

Outcomes for hepatocellular carcinoma (HCC), the most common type of liver cancer, are improved with early-stage detection. However, most cases of HCC are detected in late stages when curative treatments are no longer an option.3,4

The Oncoguard® Liver solution includes a sophisticated, yet simple, single blood test that delivers advanced sensitivity and specificity to aid consistent and reliable HCC detection. The test is complemented by a Patient Engagement Program designed to help empower patients to proactively protect their health and follow through with routine testing. The Oncoguard® Liver solution is designed with the hope of bringing better outcomes within reach for more patients at risk for HCC.

Simplifying testing to improve outcomes

Developed in collaboration with the Mayo Clinic, the Oncoguard® Liver test offers a new way to approach and detect early–stage HCC.


1Cronin KA et al (2018) Cancer.

2Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Network Open. 2021;4(4):e214708. doi:10.1001/jamanetworkopen.2021.4708

3Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi: 10.1371/journal.pmed.1001624.

4Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2019;17(5):976-987.e4. doi: 10.1016/j.cgh.2018.10.031.